Skip to main content

Table 2 Correlation of PIK3CA mutation and classic clinical characteristics with metastasis-free survival (MFS) in primary inflammatory breast cancer (IBC) patients with stage III disease (n = 114)

From: Targeted next-generation sequencing identifies clinically relevant somatic mutations in a large cohort of inflammatory breast cancer

Parameters n Univariate analysis Multivariate analysis
HR (95% CI) p a HR (95% CI) p b
Age   0.8 (0.5–1.1) 0.6 1.0 (0.5–1.7) 0.9
  ≤50 years 48     
  >50 years 66     
ER status   0.9 (0.6–1.6) 0.8 1.0 (0.5–2.0) 1.0
 Negative 67     
 Positive 47     
PR status   1.3 (0.8–2.3) 0.3 1.7 (0.8–3.5) 0.1
 Negative 82     
 Positive 32     
Her2 status   1.7 (1.0–2.8) 0.1 2.0 (1.1–3.8) 0.03
 Negative 79     
 Positive 35     
SBR grade   1.2 (0.7–2.0) 0.2 1.2 (0.7–2.2) 0.5
 III 71     
 I and II 43     
PIK3CA   2.6 (1.4–4.7) 0.002 2.7 (1.5–4.7) 0.001
 Mut-type 33     
 Wild-type 81     
  1. CI confidence interval, ER estrogen receptor, Her2 human epidermal growth factor receptor 2, HR hazard ratio, PR progesterone receptor, SBR Scarf Bloom Richardson classification
  2. a Log-rank test
  3. b Cox multivariate analyses